Supriya Lifescience Share Price

Audio Link for outcome of Results Earnings Call for United Financial Results for quarter ended June 30, 2026 is enclosed.

• BSE India
• 1 day 20 hours ago

Enclosed herewith Copy of Newspaper Publication of Results for quarter ended June 30, 2026.

• BSE India
• 1 day 20 hours ago

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Supriya Lifescience announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Revenue from Operations for Q1FY27 stood at Rs 1,897.47 million, compared to Rs 1,450.74 million in Q1FY26, marking a YoY growth of 30.79%. On a QoQ basis, revenue decreased by 31.38% from Rs 2,765.28 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total Income for Q1FY27 was Rs 1,923.95 million, up 30.22% YoY from Rs 1,477.48 million in Q1FY26 and down 31.29% QoQ from Rs 2,800.06 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Profit before Tax for Q1FY27 was Rs 407.92 million, representing a YoY decline of 13.96% from Rs 474.12 million in Q1FY26 and a QoQ decrease of 55.72% from Rs 921.29 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Net Profit for Q1FY27 stood at Rs 240.43 million, a YoY decrease of 30.89% from Rs 347.90 million in Q1FY26 and a QoQ drop of 67.61% from Rs 742.29 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total Comprehensive Income for Q1FY27 was Rs 246.90 million compared to Rs 345.75 million in Q1FY26 and Rs 742.70 million in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Basic Earnings per equity share for Q1FY27 was Rs 2.99, compared to Rs 4.32 in Q1FY26 and Rs 9.22 in Q4FY26.</li> </ul> <p><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Note on Export Sales: The company recognized a sale for material dispatched for export that was intercepted and detained by Customs and remained in Customs custody as of June 30, 2026. Since the shipment had reached Customs for export processing, the transaction was recognized as a sale in the books, and the goods were not part of the closing inventory.</li> <li _ngcontent-ng-c1940132427="">Group Structure: As of June 30, 2026, the company does not have any subsidiary, associate, or joint venture company.</li> <li _ngcontent-ng-c1940132427="">Reporting Segment: While the Chief Operating Decision Maker evaluates performance based on various indicators, the company is primarily engaged in a single business segment, which is the custom synthesis and manufacturing of specialty chemicals.</li> </ul> <p><strong>Satish Wagh, Executive Chairman and Whole-Time Director, Supriya Lifescience, commenting on the results, said</strong>, “Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets. Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across Anesthetic and ADHD, we remain focused on building sustainable long-term growth.”</p> <p><a class="lb" href="/get-document/post/pdf/5789497/" target="_blank">Result PDF</a></p>

• Trendlyne
• 2 days 1 hour ago